Novavax Issues Statement On Prototype Vaccine’s Broad Immune Responses And Accelerated Focus On Omicron Ba.4/5 As Recommended By The FDA; Says Awaiting US Emergency Use Authorization For Co’s Prototype COVID-19 Vaccine

22nd Century Group, Inc. (NASDAQ: XXII) has entered into definitive agreements with certain investors for the purchase and sale of 11.2 million shares of common stock and warrants at a price of $0.47 per share in a registered direct offering priced above market.